CEROW · Cero Therapeutics Holdings, Inc.
$0.00
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$716,309
Shares
71.63M
Volume · Oct 19
650
Avg daily vol (10 sessions)
9275
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
Available close range$0.00–0.00
Avg vol available · 10d9K
DataJul 2026–Oct 2026
Filing10-Q · Aug 14
The closing range uses available history since Jul 31, 2026; less than a full year is stored.
Up next
filed Aug 14, 2026
Technicals
trend & momentum for long-term holders illustrative — not investment adviceMarket signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its available closing range
Range low $0
Now $0 · 82%
Range high $0
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CEROW
this stock
Cero Therapeutics Holdings, Inc.
|
$716,309 | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CEROW | +105.9% | — | — | +94.4% | — |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +107.4% | — | — | +93.9% | — |